Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
종목 코드 BDSX
회사 이름Biodesix Inc
상장일Oct 28, 2020
CEOMr. Scott Hutton
직원 수273
유형Ordinary Share
회계 연도 종료Oct 28
주소919 West Dillon Road
도시LOUISVILLE
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호80027
전화13034170500
웹사이트https://www.biodesix.com/
종목 코드 BDSX
상장일Oct 28, 2020
CEOMr. Scott Hutton
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음